Disease/Infection News

RSS

Race of donor may affect recurrent hepatitis C in patients after liver transplantation: Study

The race of liver donors may affect recurrent hepatitis C in patients after liver transplant, according to a study by Henry Ford Hospital. Patients receiving white cadaveric donor grafts had significantly more aggressive recurrent hepatitis C than those receiving grafts from African-American donors regardless of recipient race, says Matthew Moeller, M.D., gastroenterology fellow at Henry Ford Hospital and lead author of the study.

1 Nov 2010

Consumption of peanut during pregnancy may increase risk of allergy in infants: Study

Researchers have found that allergic infants may be at increased risk of peanut allergy if their mothers ingested peanuts during pregnancy. The data are reported in the November 1, 2010 issue of the Journal of Allergy and Clinical Immunology.

1 Nov 2010

Study determines long-term clinical outcome of patients posttransplant after anitviral therapy

Researchers from the University of Bari, Italy, concluded that treating patients after transplantation with antiviral therapy creates a sustained viral response (SVR) and protects them from liver-related deaths. The purpose of this study was to determine the long-term clinical outcomes of patients posttransplant who underwent antiviral therapy for recurrent hepatitis C virus (HCV) infection of the liver graft.

1 Nov 2010

Boehringer to present data of SOUND-C1 Phase Ib study for HCV treatment at AASLD Meeting

Boehringer Ingelheim announced results from a Phase Ib study, SOUND-C1, that showed the combination of two oral hepatitis C virus (HCV) compounds, the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, with ribavirin reduced viral load to the lower limit of quantifiable levels in HCV treatment-naïve patients.

1 Nov 2010

Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a Phase 1 clinical trial evaluating IMO-2125, a novel immune modulator, in null-responder patients with chronic hepatitis C virus (HCV) infection.

1 Nov 2010

Scientists use electron microscopes to study mechanism of perforin protein to punch holes in rogue cells

Scientists from the UK and Australia have seen the human immune system's assassin a protein called perforin in action for the first time. The UK team, funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and the Wellcome Trust, is based at Birkbeck College where they used powerful electron microscopes to study the mechanism that perforin uses to punch holes in rogue cells.

1 Nov 2010

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Tibotec Pharmaceuticals announced today the company will present the results of a Week-24 planned interim analysis of the phase 2 response-guided PILLAR study in treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., USA. The data will be presented as part of a late-breaker oral presentation on Monday, November 1.

1 Nov 2010

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.

1 Nov 2010

Gilead presents Phase IIa data for HCV therapy at The Liver Meeting 2010

Gilead Sciences, Inc. today announced data from a Phase IIa study showing that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus (HCV) within 28 days of treatment.

1 Nov 2010

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

Anadys Pharmaceuticals, Inc. today announced the ANA598 data to be presented at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston, MA.

1 Nov 2010

Killer malaria to disappear in 10-15 years: Experts

From data gathered around the world experts predict that the deadliest type of malaria can be eradicated in 10 to 15 years. The disease affects half the global population and kills an estimated 1.2 million people worldwide every year. The organism responsible for deaths is commonly Plasmodium falciparum. The parasite is at its most deadly in sub-Saharan Africa, where 90 per cent of malaria fatalities occur.

31 Oct 2010

Progress made in universal access to HIV prevention, treatment and care under threat

A report issued today by the International AIDS Society, Universal Access: Right Here, Right Now documents the principal debates around universal access during the XVIII International AIDS Conference (AIDS 2010). The report also takes stock of progress to date and reveals the scale of the future challenge for HIV treatment and prevention at a time when new infections are outstripping those receiving treatment by five to two.

30 Oct 2010

Rite Aid to host flu shot clinics at nationwide pharmacies

With the holidays getting closer, Rite Aid is reminding people to get a flu shot so that the only thing they are spreading this season is good cheer. According to The Centers for Disease Control and Prevention (CDC), it can take up to two weeks for flu shots to be effective and protect against the flu; those who get their flu shot now can help protect themselves by the time they sit down for Thanksgiving dinner.

30 Oct 2010

New nanoparticle deodorant has antibacterial and anti-odor properties

Scientists are reporting development of a new approach for dealing with offensive household and other odors one that doesn't simply mask odors like today's room fresheners, but eliminates them at the source. Their research found that a deodorant made from nanoparticles hundreds of times smaller than peach fuzz eliminates odors up to twice as effectively as today's gold standard.

30 Oct 2010

Presidio to present PPI-461 data for HCV infection at AASLD meeting

Presidio Pharmaceuticals, Inc. announced today that Nathaniel Brown, M.D., Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD meeting in Boston, MA, on November 1, 2010.

30 Oct 2010

New MBP solution helps provide lifesaving HIV-prevention medications to mothers and babies

The Elizabeth Glaser Pediatric AIDS Foundation is pleased to partner with UNICEF and other organizations in the roll-out of the Mother-Baby Pack (MBP), an innovative solution to help bring lifesaving HIV-prevention medications to mothers and babies.

30 Oct 2010

Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne

Cipher Pharmaceuticals Inc. today announced that it has completed patient enrolment in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne.

30 Oct 2010

FDA approves Teflaro for treatment of community-acquired bacterial pneumonia

Forest Laboratories, Inc. announced today that Teflaro(ceftaroline fosamil), a broad-spectrum bactericidal cephalosporin with activity against both gram-positive and gram-negative microorganisms, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of community-acquired bacterial pneumonia (CABP), including cases caused by Streptococcus pneumoniae bacteremia, and acute bacterial skin and skin structure infection (ABSSSI), including cases caused by methicillin-resistant Staphylococcus aureus (MRSA).

30 Oct 2010

Researchers to investigate new drugs for parasitic disease

Urgently-needed new treatment for a parasitic disease is being investigated in research led at the University of Strathclyde in Glasgow, Scotland. Human African Trypanosomiasis, also known as sleeping sickness, affects between 50,000 and 70,000 people in Africa and South America. It is transmitted through the bite of the tsetse fly and attacks the nervous system and brain, leading to fever, headaches and disturbed sleep patterns.

30 Oct 2010

Lancet series examines malaria eradication goal

Eliminating malaria can be achieved only with repeated investment over the long term and will require a major shift in policy and funding, according to some experts, Reuters reports.

30 Oct 2010

Disease/Infection News

Race of donor may affect recurrent hepatitis C in patients after liver transplantation: Study

Consumption of peanut during pregnancy may increase risk of allergy in infants: Study

Study determines long-term clinical outcome of patients posttransplant after anitviral therapy

Boehringer to present data of SOUND-C1 Phase Ib study for HCV treatment at AASLD Meeting

Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting

Scientists use electron microscopes to study mechanism of perforin protein to punch holes in rogue cells

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead presents Phase IIa data for HCV therapy at The Liver Meeting 2010

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

Killer malaria to disappear in 10-15 years: Experts

Progress made in universal access to HIV prevention, treatment and care under threat

Rite Aid to host flu shot clinics at nationwide pharmacies

New nanoparticle deodorant has antibacterial and anti-odor properties

Presidio to present PPI-461 data for HCV infection at AASLD meeting

New MBP solution helps provide lifesaving HIV-prevention medications to mothers and babies

Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne

FDA approves Teflaro for treatment of community-acquired bacterial pneumonia

Researchers to investigate new drugs for parasitic disease

Lancet series examines malaria eradication goal

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News